Mylan, Inc. (MYL)
-NasdaqGS 31.17 
0.58(1.81%) May 24, 4:00PM EDT|After Hours
:
31.25 0.08 (0.24%) May 24, 6:25PM EDT
| Prev Close: | 31.75 |
|---|
| Open: | 31.53 |
|---|
| Bid: | 31.17 x 300 |
|---|
| Ask: | 32.49 x 300 |
|---|
| 1y Target Est: | 32.03 |
|---|
| Beta: | 1.21 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 31.04 - 31.69 |
|---|
| 52wk Range: | 20.50 - 32.09 |
|---|
| Volume: | 5,952,812 |
|---|
| Avg Vol (3m): | 6,208,590 |
|---|
| Market Cap: | 11.88B |
|---|
| P/E (ttm): | 20.82 |
|---|
| EPS (ttm): | 1.50 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- MYLAN INC. Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersEDGAR Online(Fri, May 24)
- The Zacks Analyst Blog Highlights: Zumiez, Mylan, AbbVie, Santarus and Jazz PharmaceuticalsZacks(Thu, May 23)
- Favorable Verdict for MylanZacks(Wed, May 22)
- Merck Enters into Strategic DealZacks(Wed, May 22)
- Generic Launches at Mylan ContinueZacks(Wed, May 22)
- Mylan's Management Presents at UBS Global Healthcare Conference (Transcript)at Seeking Alpha(Wed, May 22)
- 4 Healthcare Stock Stories For Tuesday Investment Wellnessat Wall St. Cheat Sheet(Tue, May 21)
- Actavis Lowers Tax Rate to 17% After Warner Chilcott Dealat Bloomberg(Tue, May 21)
- A Good Deal For Actavis, But Warner Chilcott Goes A Little Cheapat Investopedia(Tue, May 21)
- Paulson & Co.'s Q1 tradesat MarketWatch(Tue, May 21)
- Actavis: The latest Fortune 500 company to "leave" the U.S. for tax reasonsat Fortune(Tue, May 21)
- "Modern Family" Star Julie Bowen Calls on Communities to Raise Their Hand for Anaphylaxis Awareness in Nationwide CompetitionPR Newswire(Tue, May 21)
- Federal Appellate Court Rules in Favor of Mylan in Patent Infringement Litigation Relating to Sunovion's Brovana® ProductPR Newswire(Tue, May 21)
- Sanofi, Roll Global, Heineken, WWE: Intellectual Propertyat Bloomberg(Tue, May 21)
- Actavis buying Warner Chilcott in $8.5B dealAP(Mon, May 20)
Key Statistics
| Forward P/E (1 yr): | 9.65 |
|---|
| P/S (ttm): | 1.77 |
|---|
| Ex-Dividend Date: | 27-Jun-07 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 2.86 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.67 |
|---|
| Mean Recommendation*: | 2.3 |
|---|
| PEG Ratio (5 yr expected): | 1.26 |
|---|
Business Summary
Mylan Inc. engages in the development, manufacture, marketing, licensing, and distribution of generic and branded generic pharmaceuticals, specialty pharmaceuticals, and active pharmaceutical ingredients (APIs) worldwide.
View More